Guardant Health Q3 revenue up 39%, beats estimates

Guardant Health

29/10/2025 20:24

Overview

Guardant Health Q3 revenue grows 39% yr/yr, beating analyst expectations

Adjusted loss per share for Q3 beats consensus, reflecting operational improvements

Company raises 2025 revenue guidance to $965-$970 mln, indicating strong growth outlook

Outlook

Guardant Health raises 2025 revenue guidance to $965-$970 mln, up from $915-$925 mln

Company expects 2025 oncology revenue to grow 25% year-over-year

Screening revenue for 2025 expected between $71-$73 mln, driven by Shield tests

Result Drivers

ONCOLOGY TEST VOLUME - Co attributes 40% growth in oncology test volume to strong performance across Guardant360 Liquid, Tissue, and Reveal tests

SCREENING REVENUE - Shield screening tests generated $24.1 mln in revenue, marking significant growth from $1 mln in prior year period

STRATEGIC COLLABORATIONS - Co established partnerships with Quest Diagnostics and PathGroup to expand Shield access nationwide

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
Beat
$265.20 mln
$235.69 mln (20 Analysts)
Q3 Adjusted EPS
Beat
-$0.39
-$0.76 (11 Analysts)
Q3 EPS
-$0.74
Q3 Adjusted Net Income
Beat
-$48.30 mln
-$98.59 mln (10 Analysts)
Q3 Adjusted EBITDA
Beat
-$45.50 mln
-$55.01 mln (12 Analysts)

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 23 "strong buy" or "buy", 1 "hold" and 1 "sell" or "strong sell"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

Wall Street's median 12-month price target for Guardant Health Inc is $70.00, about 0.6% above its October 28 closing price of $69.58

Press Release: ID:nBw5MLpcNa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)